Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 1378754Generated: October 30, 2026

Phosgene → 3-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(morpholino)carbonyl]imidazo[1,5-a]quinoxaline

https://huagongshe.com/reaction/1378754

Reaction equation

Participants

RoleNameHCIDCharge
ReactantPhosgeneHCID 6371—
ReactantMorpholineHCID 8083—
ReactantDiisopropylethylamineHCID 81531—
Reactant3-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[1,5-a]quinoxalineHCID 9993744—
SolventTetrahydrofuranHCID 8028—
Product3-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(morpholino)carbonyl]imidazo[1,5-a]quinoxalineHCID 10620523—

Reaction Steps

To a slurry consisting of 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo[1,5-a]quinoxaline (XXXIII, EXAMPLE 88, 0.499 g), diisopropylethylamine (0.81 ml) and THF (15 ml) is added phosgene (1.93M in toluene, 1.20 ml). A slight exotherm ensues and the slurry becomes homogeneous. After 10 min, morpholine (0.20 ml) is added. The mixture is stirred for 2 hr and then partitioned between ethyl acetate, water, and saline. The phases are separated and the organic phase is dried over magnesium sulfate and concentrated. The crude product is chromatographed on silica gel (150 ml) eluting with methanol/dichloromethane (2/98). The appropriate fractions are pooled and concentrated to give the product. Recrystallization from dichloromethane and hexane gives the title compound, mp 198.0°-198.5°; MS (m/z) at 392; IR 1662, 1506, 1409, 1277, and 1579 cm-1 ; NMR (CDCl3) 1.24, 1.36, 2.27, 3.33, 3.64, 5.02, 7.21, 7.27, 7.55 and 8.11 δ.

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS05668282
Source datasetuspto-grants-1997_09
ORD IDord-f5056a8e854e44248350c5aaeebe7aec
Source noteuspto-grants-1997_09